Making Tradeoffs: Planning Sample Volumes
What percentage of samples dispensed support their major purpose--encouraging new courses of prescription therapy? The unsettling answer: far more than most people think.
You may also be interested in...
Because physicians' use of product samples varies across pharmaceutical classes and products in measurable ways, it behooves drug companies to start assessing how much their sampling is actually boosting market share and how much it is simply cutting their revenue-generating prescriptions.
Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.